Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,540,681.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $24,712,246.04. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

United Therapeutics Price Performance

United Therapeutics stock opened at $549.87 on Friday. The stock has a market cap of $23.34 billion, a P/E ratio of 20.30, a PEG ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s 50 day moving average price is $568.23 and its 200-day moving average price is $518.83.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the business posted $6.63 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Bank of America raised their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $619.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Wellington Management Group LLP boosted its stake in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new position in United Therapeutics during the third quarter worth $317,617,000. Norges Bank purchased a new position in United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC boosted its stake in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.